New study tests apremilast for psoriasis relief
NCT ID NCT07190391
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 4 trial will test the drug apremilast in 425 adults with moderate-to-severe psoriasis. Over 32 weeks, researchers will measure how well the drug clears skin patches and monitor for side effects. The goal is to confirm apremilast's effectiveness and safety in a real-world setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- apremilast (tablet)
- What this could lead to
- If successful, this could confirm apremilast as a safe and effective option for controlling moderate-to-severe psoriasis symptoms.
- What could go wrong
- This is a single-arm, open-label study, so results may be less reliable than a blinded trial. Apremilast can cause side effects like nausea, diarrhea, and headache.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new daily pill quiet the immune attack behind psoriasis?
- Laser boost for stubborn psoriasis on hands and feet
- New oral pill HPP737 takes on psoriasis in Head-to-Head trial
- New oral pill HPP737 aims to clear psoriasis in phase 3 trial
- Psoriasis Patients' quality of life under the microscope
- Skin disease evolution under the microscope: a 17-Year look at what drives severity